The study showed that 111In-labeled anti-HER2 VHHs display high specific uptake in HER2 positive brain tumor from 1 h up to three days post injection, whereas 111In-labeled mAb Trastuzumab causes high non-specific uptake in highly vascularized organs including heart, spleen and liver (26). Here, ERBB2 is linked to brain neoplasm.